Every year, thousands of Canadians undergo blood and marrow transplantation (BMT). For patients with blood cancers like leukemia and lymphoma, BMT might be an essential part of their treatment plan. In other patients with inherited blood or immune disorders, BMT can offer a potential cure.
The vision of the CBMTG is that Canada will be the best place in the world to have a blood and marrow transplant. The mission of the association is that “the Canadian Blood and Marrow Transplant Group is the voice of experts working in the field of blood and marrow transplant.”
Most countries worldwide have national blood and marrow transplant (BMT) registries, containing clinical data on autologous and allogeneic BMTs. While Canada has a proven track record of leading edge clinical trials and clinical centres delivering leading transplant care, Canada has lacked a well-developed BMT registry. The executive of the Canadian Blood and Marrow Transplant Group identified this as a priority for the Canadian transplant community.Over the past two years, this project has become a reality. The CBMTG has developed a comprehensive registry containing detailed clinical outcomes on Canadians undergoing autologous and allogeneic centres across Canada. This registry will be used for transplant research in Canada, and will be an invaluable tool for the Canadian BMT community.
One of the ways that we can provide the best care for future Canadians who need a BMT is to learn from the experiences of the Canadians who have previously undergone transplant. For example, the transplant physician and patient might be faced with a decision between two different treatment options. Registry research can compare patients who have had these two treatment options in the past, to find out which might be best for this given patient.
There are currently data on over 8000 patients in the CBMTG Registry, and this number is growing daily. Through knowledge gained from the patients in the registry we hope to improve outcomes for the patients of tomorrow.